Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. The company completed its IPO [NASDAQ: RXRX] in 2021.

Recursion Pharma is a Salt Lake City-based drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition known drugs and shelved pharmaceutical assets to treat rare genetic diseases and other conditions.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2016
  • IPO: 2021

• Founders

  • Chris Gibson, PhD
  • Blake Borgeson, PhD
  • Dean Li, PhD

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • Today, we announced that Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. & Glenn Morrison, Ph.D. are joining the Recursion… https://t.co/KwXZrGLIj0@RecursionPharma - 4h
  • Happy Thanksgiving! We're thankful for our incredible team of #Recursionauts working to positively impact patients… https://t.co/oLVsKrSE3G@RecursionPharma - 03:07 PM Nov 26th
  • We’re hiring a Senior Product Manager, Digital Chemistry to translate company-level strategy into internal developm… https://t.co/rWVZH22bOr@RecursionPharma - 04:02 PM Nov 23rd